Improved long-term biocompatibility of coronary stents by plasma coating process Abstract Drug-eluting stents (DES) have been widely used to treat patients of coronary heart disease (CHD) due to their better ability to control restenosis than bare metal stents (BMS). However, there is a high risk of late in-stent thrombosis associated with DES after implantation in patients, which could lead to fatal heart attack and death even though it occurs at low rate. Thus, for safe and effective clinical use, a coronary stent needs to have better long-term biocompatibility on its surface that will provide sufficient thrombo-resistance in addition to inhibiting smooth muscle cell proliferation thereby slowing down healing of tissues around the stent. Nanova, Inc. is developing a novel coating layer of high thrombo-resistance on the surface of stents made of stainless steel or CrCo. An environmentally benign technology, low temperature plasma process is used to deposit an ultra-thin (nano-scale) but continuous layer of coating, sufficient to generate desired abrasion resistance and immobilize the bioactive functional groups created in the subsequent surface treatment to prevent blood clotting and restenosis, but thin enough to allow for stent expansion without cracking when delivered into the atherosclerotic coronary arteries of patients. The knowledge gained in this innovative research project will also benefit research and development for improved biocompatibility for other implantable medical devices such as pacemakers, pulse generators, cardiac defibrillators and bio-sensors.

Public Health Relevance

Nanova, Inc. is developing and commercializing a novel nanocoating technology for application to coronary stents to prevent both restenosis (re-narrowing) of coronary arteries and late in-stent thrombosis (blood clots in stents) for safer and more effective treatment of coronary heart disease, which will benefit over one million of patients in the United States.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Lee, Albert
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nanova, Inc.
United States
Zip Code
Jones, John Eric; Chen, Meng; Chou, Ju et al. (2017) Electrochemical study on the corrosion resistance of plasma nanocoated 316L stainless steel in albumin- and lysozyme-containing electrolytes. Curr Top Electrochem 19:1-15
Jones, John Eric; Yu, Qingsong; Chen, Meng (2017) A chemical stability study of trimethylsilane plasma nanocoatings for coronary stents. J Biomater Sci Polym Ed 28:15-32
Xu, Yuanxi; Jones, John E; Yu, Haiqing et al. (2015) Nanoscale Plasma Coating Inhibits Formation of Staphylococcus aureus Biofilm. Antimicrob Agents Chemother 59:7308-15
Eric Jones, John; Chen, Meng; Yu, Qingsong (2014) Corrosion resistance improvement for 316L stainless steel coronary artery stents by trimethylsilane plasma nanocoatings. J Biomed Mater Res B Appl Biomater 102:1363-74
Chen, Meng; Yu, Qingsong; Sun, Hongmin (2013) Novel strategies for the prevention and treatment of biofilm related infections. Int J Mol Sci 14:18488-501
Ma, Yibao; Chen, Meng; Jones, John E et al. (2012) Inhibition of Staphylococcus epidermidis biofilm by trimethylsilane plasma coating. Antimicrob Agents Chemother 56:5923-37